High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy

Hdl Handle:
http://hdl.handle.net/10144/120333
Title:
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy
Authors:
Laurent, C; Bourgeois, A; Mpoudi-Ngolé, E; Kouanfack, C; Ciaffi, L; Nkoué, N; Mougnutou, R; Calmy, A; Koulla-Shiro, S; Ducos, J; Delaporte, E
Journal:
HIV medicine
Abstract:
OBJECTIVES: To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon. METHODS: Baseline blood samples from 169 patients were tested retrospectively for hepatitis B surface antigens (HBsAg), anti-hepatitis B core (anti-HBc), anti-HCV and - if HBsAg or anti-HCV result was positive or indeterminate - for HBV DNA or HCV RNA, respectively, using the Cobas Ampliprep/Cobas TaqMan quantitative assay (Roche Diagnostics GmbH, Mannheim, Germany). RESULTS: HBV DNA was detected in 14 of the 18 patients with positive or indeterminate HBsAg results [8.3% of the total study population, 95% confidence interval (CI) 4.6-13.5]. The median HBV viral load was 2.47 x 10(7) IU/mL [interquartile range (IQR) 3680-1.59 x 10(8); range 270 to >2.2 x 10(8)]. Twenty-one patients (12.4%, 95% CI 7.9-18.4) were found with HCV RNA (all with positive HCV serology). The median HCV viral load was 928 000 IU/mL (IQR 178 400-2.06 x 10(6); range 640-5.5 x 10(6)). No patient was co-infected with HBV and HCV. In multivariate analysis, HCV co-infection was associated with greater age [>or=45 years vs. <45 years, odds ratio (OR) 11.89, 95% CI 3.49-40.55, P<0.001] and abnormal serum alanine aminotransferase level [>or=1.25 x upper limit of normal (ULN) vs. <1.25 x ULN, OR 7.81, 95% CI 1.54-39.66, P=0.01]; HBV co-infection was associated with abnormal serum aspartate aminotransferase level (OR 4.33, 95% CI 1.32-14.17, P=0.02). CONCLUSIONS: These high rates of active HBV and HCV co-infections in HIV-positive Cameroonian patients requiring antiretroviral therapy underline the need to promote: (i) screening for HBV and HCV before treatment initiation; (ii) accessibility to tenofovir (especially in HBV-endemic African countries); and (iii) accessibility to treatment for HBV and HCV infections.
Affiliation:
Institut de Recherche pour le Développement, University Montpellier 1, Montpellier, France; Department of Infectious and Tropical Diseases, University Hospital, Montpellier, France; Military Hospital, Yaounde, Cameroon; Central Hospital, Yaounde, Cameroon; Medecins Sans Frontieres, Geneva, Switzerland; Laboratory of Viral Hepatitis, University Hospital, Montpellier, France
Issue Date:
29-Jul-2009
URI:
http://hdl.handle.net/10144/120333
DOI:
10.1111/j.1468-1293.2009.00742.x
PubMed ID:
19659944
Additional Links:
http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1464-2662&date=2010&volume=11&issue=1&spage=85
Submitted date:
2010-10-15
Type:
Article
Language:
en
ISSN:
1468-1293
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorLaurent, Cen
dc.contributor.authorBourgeois, Aen
dc.contributor.authorMpoudi-Ngolé, Een
dc.contributor.authorKouanfack, Cen
dc.contributor.authorCiaffi, Len
dc.contributor.authorNkoué, Nen
dc.contributor.authorMougnutou, Ren
dc.contributor.authorCalmy, Aen
dc.contributor.authorKoulla-Shiro, Sen
dc.contributor.authorDucos, Jen
dc.contributor.authorDelaporte, Een
dc.date.accessioned2011-01-25T16:46:46Z-
dc.date.available2011-01-25T16:46:46Z-
dc.date.issued2009-07-29-
dc.date.submitted2010-10-15-
dc.identifier.citationHIV Med.2010;11 (1):85-9en
dc.identifier.issn1468-1293-
dc.identifier.pmid19659944-
dc.identifier.doi10.1111/j.1468-1293.2009.00742.x-
dc.identifier.urihttp://hdl.handle.net/10144/120333-
dc.description.abstractOBJECTIVES: To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon. METHODS: Baseline blood samples from 169 patients were tested retrospectively for hepatitis B surface antigens (HBsAg), anti-hepatitis B core (anti-HBc), anti-HCV and - if HBsAg or anti-HCV result was positive or indeterminate - for HBV DNA or HCV RNA, respectively, using the Cobas Ampliprep/Cobas TaqMan quantitative assay (Roche Diagnostics GmbH, Mannheim, Germany). RESULTS: HBV DNA was detected in 14 of the 18 patients with positive or indeterminate HBsAg results [8.3% of the total study population, 95% confidence interval (CI) 4.6-13.5]. The median HBV viral load was 2.47 x 10(7) IU/mL [interquartile range (IQR) 3680-1.59 x 10(8); range 270 to >2.2 x 10(8)]. Twenty-one patients (12.4%, 95% CI 7.9-18.4) were found with HCV RNA (all with positive HCV serology). The median HCV viral load was 928 000 IU/mL (IQR 178 400-2.06 x 10(6); range 640-5.5 x 10(6)). No patient was co-infected with HBV and HCV. In multivariate analysis, HCV co-infection was associated with greater age [>or=45 years vs. <45 years, odds ratio (OR) 11.89, 95% CI 3.49-40.55, P<0.001] and abnormal serum alanine aminotransferase level [>or=1.25 x upper limit of normal (ULN) vs. <1.25 x ULN, OR 7.81, 95% CI 1.54-39.66, P=0.01]; HBV co-infection was associated with abnormal serum aspartate aminotransferase level (OR 4.33, 95% CI 1.32-14.17, P=0.02). CONCLUSIONS: These high rates of active HBV and HCV co-infections in HIV-positive Cameroonian patients requiring antiretroviral therapy underline the need to promote: (i) screening for HBV and HCV before treatment initiation; (ii) accessibility to tenofovir (especially in HBV-endemic African countries); and (iii) accessibility to treatment for HBV and HCV infections.en
dc.language.isoenen
dc.relation.urlhttp://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1464-2662&date=2010&volume=11&issue=1&spage=85en
dc.rightsArchived with thanks to HIV medicineen
dc.subject.meshAdenineen
dc.subject.meshAdulten
dc.subject.meshAge Factorsen
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAnti-Retroviral Agentsen
dc.subject.meshCameroonen
dc.subject.meshComorbidityen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHIV-1en
dc.subject.meshHepacivirusen
dc.subject.meshHepatitis Ben
dc.subject.meshHepatitis B Surface Antigensen
dc.subject.meshHepatitis Cen
dc.subject.meshHepatitis C Antibodiesen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshMultivariate Analysisen
dc.subject.meshPhosphonic Acidsen
dc.subject.meshPregnancyen
dc.subject.meshRetrospective Studiesen
dc.subject.meshTransaminasesen
dc.titleHigh rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapyen
dc.typeArticleen
dc.contributor.departmentInstitut de Recherche pour le Développement, University Montpellier 1, Montpellier, France; Department of Infectious and Tropical Diseases, University Hospital, Montpellier, France; Military Hospital, Yaounde, Cameroon; Central Hospital, Yaounde, Cameroon; Medecins Sans Frontieres, Geneva, Switzerland; Laboratory of Viral Hepatitis, University Hospital, Montpellier, Franceen
dc.identifier.journalHIV medicineen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.